Matinas BioPharma Holdings (MTNB) Other Non Operating Income (2020 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Other Non Operating Income of $15000.0 for Q1 2026, up 475.0% year-over-year from $2608.7 in Q1 2025, and up 106.28% quarter-over-quarter from -$239000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Other Non Operating Income (2020 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Other Non Operating Income for 7 consecutive years, with $15000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non Operating Income rose 475.0% year-over-year to $15000.0; the TTM figure through Mar 2026 stood at -$242000.0 (down 235.96% YoY), while the FY2025 annual figure was -$261000.0, down 199.62% from the prior year.
- Other Non Operating Income rose to $15000.0 in Q1 2026 per MTNB's latest filing, from -$239000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $120000.0 in Q2 2024 and bottomed at -$239000.0 in Q4 2025.
- Historically, Other Non Operating Income has averaged $26822.8 across 5 years, with a median of $45000.0 in 2025.
- Annual changes were most pronounced in 2023 — Other Non Operating Income soared 7895.95% — and 2025, when it slumped 443.18%.
- Matinas BioPharma Holdings' Other Non Operating Income stood at $89000.0 in 2022, then changed by 0.0% to $89000.0 in 2023, then slumped by 149.44% to -$44000.0 in 2024, then plunged by 443.18% to -$239000.0 in 2025, then jumped by 106.28% to $15000.0 in 2026.
- Business Quant data shows MTNB's Other Non Operating Income at $15000.0 in Q1 2026, -$239000.0 in Q4 2025, and $45000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,000.00 |
| Mar 31, 2026 | 15,000.00 |
| Dec 31, 2025 | -239,000.00 |
| Sep 30, 2025 | 45,000.00 |
| Jun 30, 2025 | -63,000.00 |
| Mar 31, 2025 | -4,000.00 |
| Dec 31, 2024 | -44,000.00 |
| Sep 30, 2024 | 106,000.00 |
| Jun 30, 2024 | 120,000.00 |
| Mar 31, 2024 | 78,000.00 |
| Dec 31, 2023 | 89,000.00 |
| Sep 30, 2023 | 79,000.00 |
| Jun 30, 2023 | 99,000.00 |
| Mar 31, 2023 | 73,000.00 |
| Dec 31, 2022 | 89,000.00 |
| Sep 30, 2022 | 988.00 |
| Jun 30, 2022 | 2,000.00 |
| Mar 31, 2022 | 10,000.00 |
| Dec 31, 2021 | 15,702.00 |
| Sep 30, 2021 | 41,394.00 |